Akebia Launches Phase 2 Trial for Ebribafusp in Rare Kidney Diseases
Event summary
- Akebia Therapeutics initiated a Phase 2 basket trial to study ebribafusp in rare kidney diseases including IgAN, LN, and C3G.
- The trial will enroll up to 30 patients and measure safety, efficacy, and pharmacokinetics over 26 weeks with a long-term extension for responders.
- Ebribafusp is designed to inhibit complement activation in tissues without affecting the blood complement system.
- Akebia acquired global rights to ebribafusp from Q32 Bio in November 2025.
The big picture
Akebia's Phase 2 trial for ebribafusp targets a significant unmet need in rare kidney diseases, where current treatments often fall short. The trial's design aims to address both safety and efficacy concerns associated with systemic complement inhibition. Success could position Akebia as a key player in the growing field of targeted therapies for complement-mediated conditions.
What we're watching
- Clinical Efficacy
- How ebribafusp's ability to reduce complement activation in kidney tissue without inhibiting blood complement will impact trial outcomes.
- Regulatory Pathway
- Whether the Phase 2 data will support further development and potential approval for rare kidney diseases.
- Competitive Landscape
- The pace at which Akebia can differentiate ebribafusp from existing complement inhibitors in the market.
Related topics